LY 3002813

Next Previous
Drug Profile

LY 3002813

Alternative Names: LY3002813; LY3002813-IV; LY3002813-SC; N3pG-AB-monoclonal-antibody-Eli-Lilly; N3pG-amyloid-beta Monoclonal Antibody

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 18 Dec 2017 Phase-II clinical trials in Alzheimer's disease (In the elderly, Monotherapy, Combination therapy) in USA (IV) (NCT03367403)
  • 13 Dec 2017 Phase I development is ongoing in USA and Japan (SC, IV)
  • 08 Dec 2017 Eli Lilly plans a phase II trial in Alzheimer's disease (Monotherapy, Combination therapy, In the elderly) in December 2017 (IV)(NCT03367403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top